Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on ATHERSYS INC. We currently have 6 research reports from 1 professional analysts.
Frequency of research reports
Research reports on
Progress on all fronts
27 Oct 16
Recently, Athersys reported progress with both US and Japanese regulatory authorities. The company reached a deal with the FDA for the design of its pivotal Phase III trial for MultiStem in ischemic stroke under a Special Protocol Assessment (SPA) and should be able to file with just one 300-patient Phase III trial run in North America and Europe. Other clinical data, including the results of its trial in Japan (the design of which has just been accepted by the PMDA), will be used to support the NDA.
On track for a big Japanese trial
30 Jun 16
Athersys and its Japanese development partner Healios are on track to begin a 150-200 patient registration trial for MultiStem in stroke in Japan. We expect the company to file an IND with the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) in mid-summer and begin enrolling patients in Q416. Importantly, a successful trial of this size could enable them to gain full approval in Japan instead of conditional approval and could potentially be used as part of a registration package in the US.
A bigger, better Japanese partnership
04 Mar 16
Athersys has made progress on a number of clinical and commercial fronts in the first months of 2016. Most recently, it reported a one-year follow-up from the Phase II stroke trial, which showed that patients receiving MultiStem improved significantly more than placebo over the course of the year. Also, Athersys and Healios K.K. announced a partnership to commercialize MultiStem in Japan for ischemic stroke with the option to develop other indications. The company expects to initiate a stroke trial in Japan in H216.
MultiStem signal in stroke
14 Dec 15
Athersys is developing off-the-shelf multipotent adult progenitor cells (MAPCs) to treat a variety of indications, with ischemic stroke, acute myocardial infarction (AMI) and acute respiratory distress syndrome (ARDS) the most advanced. The recent Phase II data in stroke indicated strong trends in favor of MultiStem across multiple endpoints, though the study did miss the primary endpoint on an intent-to-treat basis. Clinical trial design changes in future trials should help increase the program’s chance of success. We value Athersys at $4.08 per share.
One door closes, another one opens
21 Oct 15
Today, Athersys announced that the agreement between the company and Chugai to develop and commercialize MultiStem in Japan has ended following the failure of negotiations to modify the financial terms of the agreement and to decide on a development strategy. However, Athersys also announced that it has already signed a letter of intent with another Japanese company to develop and commercialize MultiStem in Japan in ischemic stroke and other areas.
More clarity on ischaemic stroke
19 Aug 15
In its Q215 earnings release, Athersys provided much needed additional data with regard to its Phase II MultiStem trial in ischaemic stroke, which had missed the primary endpoint. Changes in the trial design aimed at accelerating enrolment led to the inclusion of patients both less likely to respond to MultiStem and more likely to respond to standard of care. If the original trial design had been in place, the additional data suggest the trial may have been positive. Our fair value increases to $256m or $3.09 per share as we increase the probability of success to 25% from 20%.
N+1 Singer - Small-cap quantitative research - Momentum screen refresh + 10 focus stocks
12 Jan 17
We have refreshed our momentum style screen for the first time since inception on 26 July 2016. As before, the screen selects the 25 stocks exhibiting the most extreme momentum characteristics, according to our measurement method. From these we have selected 10 to focus on. Since inception the screen has underperformed both the main small-cap and micro-cap indices against a background of generally rising momentum. We have noted a subset of the basket, where decelerating momentum at the time of measurement appears correlated with significant share price falls since selection. We shall monitor this factor with the new screen, albeit there are only two such stocks showing this pattern, namely Lamprell (not rated) and Gear4music (not rated).
N+1 Singer - Morning Song 12-01-2017
12 Jan 17
As anticipated, the second half has again been stronger than H1 and results will be broadly in line with expectations. In line with this, the order book has continued to grow and is at record levels. This confirms that significant progress has been made in the Group’s shift towards its Technology Products division which, as targeted, contributed c.60% of group revenue in FY16. The small acquisition of Cable Power also gives a complementary boost to the product range. It is also worth noting the significant reduction in net debt, £1.0m ahead of our forecast. We remain supportive of the Group’s strategy and continue to see a bright future as this transition towards a design led technology solutions business continues. We look forward to more detail in March at the final results.
N+1 Singer - Best Ideas 2017 - Top picks
04 Jan 17
Today we publish our Best Ideas for 2017 - 12 stocks that we believe have excellent prospects in the current year together with a detailed discussion of what we see as the key sector and market themes for 2017. Our top picks are Cineworld, Elementis, Herald Investment Trust, Hill & Smith, IQE, MySale, Redde, ReNeuron, RhythmOne, SDL, Servelec and Severfield.
The Monthly January 2017
09 Jan 17
Despite all the hullaballoo of the Brexit vote and the subsequent election of Donald Trump as the next US President, the UK stock market prospered last year, especially in the latter few months of 2016. The combination of a depreciating currency – making $ earnings more valuable in relative terms - and the Trump emphasis on infrastructure expenditure drove the stock market higher
11 Jan 17
Joules Group (JOU): Strong festive trading (BUY) | Shoe Zone (SHOE): Tough FY16 could be just the beginning (HOLD) | H&T (HAT): Alternative lender emerging (BUY) | Omega Diagnostics* (ODX): ISO accreditation received for Pune, India (CORP) | Redcentric* (RCN): Interims – restoring forecasts (CORP)
Small Cap Breakfast
17 Jan 17
Global Energy Development (GED.L) — To be renamed Nautilus Marine Services. Schedule 1 from developer and seller of hydrocarbons and related products. Reverse takeover. Raising $10.5m via a convertible. Expected 9 Feb. Eco (Atlantic) Oil & Gas—TSX-V listed oil and gas exploration has announced its intention to float on AIM. Assets in Guyana and Namibia. Proposed £2m-£3m fundraise. Diversified Gas & Oil—According to LSE website first day of trading on AIM now expected for 30 January.